Company Dossier · Health Care
Zimmer Biomet
- S&P 500
- Russell 1000
What Zimmer Biomet is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $8.51 billion, up 8.7% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $1.52 billion, up 3.4% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.22 billion, up 16% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.49 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $2.49 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 5, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
- Guidance in the last 90 days: 4 outlook figures raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 20, 2026): 4 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $0.8 million on the open market.SEC Form 4
- 915 institutional managers reported a position at June 30, 2026 (−4 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 23 (58 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Zimmer Biomet is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Hedging
Expanding ↔ Retrenching
Steady
- Capital spending68th pct
- Debt raised—
- Buybacks vs capex38th pct
- Hiring filings87th pct
- Deals and private raises46th pct
- Patent publications11th pct
Confident ↔ Hedging
Hedging
- Call sentiment76th pct
- Call confidence61st pct
- Guidance changes97th pct
- Risk factors added11th pct
- Insider open-market trades44th pct
- + Guidance changes
- + Call sentiment
- − Risk factors added
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver69th pct
- Stress filings48th pct
Credit
How these are built →Zimmer Biomet's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$7.5B
- Due within a year $1.2B
- Longer term $6.3B
- Default point $4.3B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Feb 11, 2025 | $600M | 4.700% | 2027 (2y) | +45bp | 4.742% |
| Feb 11, 2025 | $550M | 5.050% | 2030 (5y) | +72bp | 5.092% |
| Feb 11, 2025 | $600M | 5.500% | 2035 (10y) | +97bp | 5.509% |
| Nov 13, 2024 | €700M | 3.518% | 2032 (8y) | +125bp | 3.518% |
| Aug 8, 2024 | $700M | 5.200% | 2034 (10y) | +120bp | 5.200% |
| Nov 28, 2023 | $500M | 5.350% | 2028 (5y) | +103bp | 5.358% |
From the pricing term sheets Zimmer Biomet filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Zimmer Biomet, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralCiti Initiates 90-Day Watch on Zimmer Biomet (ZBH) Ahead of Q3 Earnings
gurufocus.com · via Marketaux · Oct 5, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (THE MCMANUS GROUP)third_quarter 2026 · $0.1 million
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 16, 2026LobbyingLobbying report (ZIMMER BIOMET, INC.)third_quarter 2026 · $0.2 million
- Oct 13, 2026Patent
- Oct 6, 2026Patent
- Oct 6, 2026Patent
- Sep 8, 20268-KDirector or officer changeItem 5.02
- Jul 20, 2026LobbyingLobbying report (THE MCMANUS GROUP)second_quarter 2026 · $0.1 million
- Jul 15, 2026LobbyingLobbying report (ZIMMER BIOMET, INC.)second_quarter 2026 · $0.2 million
- Jun 29, 20268-KMaterial agreement signedItem 1.01
- Jun 29, 20268-KMaterial agreement terminatedItem 1.02
- May 27, 20268-KShareholder vote resultsItem 5.07
- Apr 28, 20268-KDirector or officer changeItem 5.02
- Apr 20, 2026LobbyingLobbying report (THE MCMANUS GROUP)first_quarter 2026 · $0.1 million
- Apr 19, 2026LobbyingLobbying report (ZIMMER BIOMET, INC.)first_quarter 2026 · $0.2 million
- Feb 20, 202610-KAnnual report (10-K)4 risk factors added, 0 removed
- Jan 20, 2026LobbyingLobbying report (THE MCMANUS GROUP)fourth_quarter 2025 · $0.1 million
- Jan 15, 2026LobbyingLobbying report (ZIMMER BIOMET, INC.)fourth_quarter 2025 · $0.2 million
- Jan 12, 20268-KDirector or officer changeItem 5.02
- Jun 30, 20258-KMaterial agreement signedItem 1.01
- Jun 30, 20258-KMaterial agreement terminatedItem 1.02
- Jun 3, 20258-KDirector or officer changeItem 5.02
- Jun 3, 20258-KShareholder vote resultsItem 5.07
- May 27, 20258-KDirector or officer changeItem 5.02
- Feb 25, 20258-KDirector or officer changeItem 5.02
- Feb 25, 202510-KAnnual report (10-K)2 risk factors added, 1 removed
- Feb 19, 20258-KMaterial agreement signedItem 1.01
- Feb 18, 20258-KMaterial agreement signedItem 1.01
- Jan 29, 20258-KMaterial agreement signedItem 1.01
- Nov 20, 20248-KMaterial agreement signedItem 1.01
- Nov 19, 20248-KMaterial agreement signedItem 1.01
- Feb 23, 202410-KAnnual report (10-K)0 risk factors added, 0 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Intuitive Surgical ISRG | $11.0B | $3.2B | Jun 30, 2026 |
| Edwards Lifesciences EW | $6.5B | $1.4B | Jun 30, 2026 |
| Baxter International BAX | $11.5B | — | Jun 30, 2026 |
| Steris STE | $6.0B | $0.9B | Jun 30, 2026 |
| ResMed| RMD | $5.7B | $1.6B | Jun 30, 2026 |
| Dexcom DXCM | $5.0B | $1.4B | Jun 30, 2026 |
| Idexx Laboratories IDXX | $4.5B | $1.3B | Jun 30, 2026 |
| Bruker BRKR | $3.5B | $0.1B | Jun 30, 2026 |